10-Q: Avanos Medical Reports Mixed Q3 Results Amidst Restructuring Efforts

Avanos Medical's third-quarter results show a slight decrease in net sales, offset by improvements in operating profit, as the company continues its restructuring and transformation initiatives.

Summary

• Avanos Medical reported net sales of $170.4 million for the third quarter of 2024, a slight decrease of 0.5% compared to the same period last year.
• The company's operating profit for the quarter was $12.0 million, a significant improvement from $1.2 million in the third quarter of 2023.
• For the first nine months of 2024, net sales totaled $508.2 million, a 1.6% increase year-over-year.
• The company incurred $6.4 million in restructuring costs related to the post-Respiratory Health divestiture plan and $5.2 million related to the ongoing transformation process in the first nine months of 2024.
• Avanos completed the divestiture of its Respiratory Health business on October 1, 2024, and expects to finalize adjustments to its pretax loss on discontinued operations in the fourth quarter of 2024.
• The company's gross profit margin decreased to 54.5% in Q3 2024 from 55.8% in Q3 2023, primarily due to restructuring costs and plant separation costs.
• Avanos repurchased $12.7 million of its common stock in the first nine months of 2024.
• The company's cash and cash equivalents increased slightly to $89.0 million as of September 30, 2024, compared to $87.7 million at the end of 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to improved operating profit and strategic divestiture, but tempered by slight sales decrease and restructuring costs.

Positives

• Operating profit showed a substantial improvement year-over-year, indicating better cost management and operational efficiency.
• Net sales for the first nine months of 2024 increased by 1.6% year-over-year, demonstrating growth in the core business.
• The completion of the Respiratory Health divestiture allows the company to focus on its core markets.
• The company has a strong cash position with $89.0 million in cash and cash equivalents.
• The company is actively managing its capital through share repurchases.

Negatives

• Net sales for the third quarter of 2024 decreased slightly by 0.5% compared to the same period last year.
• Gross profit margin decreased to 54.5% in Q3 2024 from 55.8% in Q3 2023, primarily due to restructuring and plant separation costs.
• The company incurred significant restructuring costs of $6.4 million related to the post-Respiratory Health divestiture plan in the first nine months of 2024.
• The company experienced lower demand for surgical pain products and lower demand and pricing for HA products.

Risks

• The company is subject to risks associated with doing business outside of the United States, including compliance with foreign laws and regulations, tariffs, and trade restrictions.
• The company's manufacturing operations are concentrated in Mexico, which exposes it to supply chain and operational risks.
• The company is subject to ongoing restructuring and transformation initiatives, which may result in additional costs and disruptions.
• The company faces competitive pressures and the risk of losing customers or failing to obtain new ones.
• The company is subject to cybersecurity threats and potential breaches of its information systems.
• The company is subject to litigation and enforcement actions.

Future Outlook

The company expects its transformation process to be substantially complete by the end of 2025 and anticipates total gross savings of between $45.0 million and $55.0 million compared to 2022, most of which will be achieved in 2024. The company also expects to finalize adjustments to its pretax loss on discontinued operations in the fourth quarter of 2024.

Management Comments

• Management is focused on aligning the organizational structure and operational footprint with the remaining business after the divestiture of the Respiratory Health business.
• Management expects the transformation process to enhance the company's operating profitability and pursue efficient capital allocation strategies.

Industry Context

The medical device industry is characterized by extensive patent litigation and regulatory compliance requirements. Avanos is navigating these challenges while also undergoing significant restructuring and portfolio rationalization. The company's focus on pain management and digestive health aligns with broader trends in healthcare towards minimally invasive procedures and improved patient nutrition.

Comparison to Industry Standards

• Avanos's gross profit margin of 54.5% in Q3 2024 is slightly below the average for medical device companies, which typically range from 55% to 65%.
• The company's operating profit margin of 7.0% in Q3 2024 is lower than some of its larger competitors, such as Medtronic and Stryker, which often achieve operating margins in the range of 15% to 25%.
• The company's restructuring efforts are similar to those undertaken by other medical device companies seeking to streamline operations and improve profitability.
• The divestiture of the Respiratory Health business is a strategic move to focus on higher-growth areas, a common strategy in the industry.
• The acquisition of Diros Technology Inc. is in line with the industry trend of consolidation and expansion into specialized therapeutic areas.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various legal proceedings, claims, and governmental investigations, but believes that the ultimate resolution of any pending legal proceeding will not have a material adverse effect on its business.

Stakeholder Impact

• Shareholders may see a positive impact from the company's restructuring efforts and improved profitability.
• Employees may be affected by the ongoing restructuring, including potential job losses.
• Customers may experience changes in product offerings and services as the company focuses on its core markets.
• Suppliers may be impacted by changes in the company's supply chain and manufacturing operations.
• Creditors may be affected by the company's debt obligations and financial performance.

Next Steps

• The company will continue to execute its restructuring plan, which is expected to be substantially complete by the end of 2025.
• Avanos will finalize adjustments to its pretax loss on discontinued operations in the fourth quarter of 2024.
• The company will continue to focus on its core markets in pain management and digestive health.

Key Dates

Keywords

restructuring, divestiture, medical devices, operating profit, net sales, financial results, transformation, respiratory health, pain management, digestive health